208 related articles for article (PubMed ID: 9829706)
1. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
2. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
3. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
4. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
Boyle JO; Meyskens FL; Garewal HS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
[TBL] [Abstract][Full Text] [Related]
5. Levels of colorectal ornithine decarboxylase activity in patients with colon cancer, a family history of nonpolyposis hereditary colorectal cancer, and adenomas.
Love RR; Surawicz TS; Morrissey JF; Verma AK
Cancer Epidemiol Biomarkers Prev; 1992; 1(3):195-8. PubMed ID: 1306105
[TBL] [Abstract][Full Text] [Related]
6. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
7. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
Pendyala L; Creaven PJ; Porter CW
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
[TBL] [Abstract][Full Text] [Related]
8. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
[TBL] [Abstract][Full Text] [Related]
9. Sources of variability in estimating ornithine decarboxylase activity and polyamine contents in human colorectal mucosa.
Hixson LJ; Emerson SS; Shassetz LR; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):317-23. PubMed ID: 8061580
[TBL] [Abstract][Full Text] [Related]
10. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
11. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
13. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
14. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine.
Gerner EW; Garewal HS; Emerson SS; Sampliner RE
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):325-30. PubMed ID: 8061581
[TBL] [Abstract][Full Text] [Related]
16. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
[TBL] [Abstract][Full Text] [Related]
17. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa.
Hixson LJ; Garewal HS; McGee DL; Sloan D; Fennerty MB; Sampliner RE; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1993; 2(4):369-74. PubMed ID: 8348060
[TBL] [Abstract][Full Text] [Related]
18. Dissimilar activation patterns of the carcinogen dimethylhydrazine (DMH) on intracellular polyamine metabolism in various organs.
Löser C; Starp F; Fölsch UR
Z Gastroenterol; 1996 Dec; 34(12):801-8. PubMed ID: 9017896
[TBL] [Abstract][Full Text] [Related]
19. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
20. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
Ajani JA; Ota DM; Grossie VB; Levin B; Nishioka K
Cancer Res; 1989 Oct; 49(20):5761-5. PubMed ID: 2507135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
